

Specimen Collected: 8/17/2026 14:56 MDT**Tgt drug prof, MassSpec/EMIT, UR, |Received: 8/18/2026 15:43 MDT Report/Verified: 8/18/2026 16:19 MDT**

Procedure	Result	Units	Reference Interval
Creatinine, Urine	400.0	mg/dL	[20.0-400.0]
6-acetylmorphine, U	See Note ⁱ¹		
7-Aminoclonazepam, U	See Note ⁱ²		
Alpha-OH-Alprazolam, U	See Note ⁱ³		
Alpha-OH-Midazolam, U	See Note ⁱ⁴		
Alprazolam, U	See Note ⁱ⁵		
Amphetamine, U	See Note ⁱ⁶		
Buprenorphine, U	See Note ⁱ⁷		
Clonazepam, U	See Note ⁱ⁸		
Codeine, U	See Note ⁱ⁹		
Diazepam, U	See Note ⁱ¹⁰		
Fentanyl, U	See Note ⁱ¹¹		
Gabapentin, U	See Note ⁱ¹²		
Hydrocodone, U	See Note ⁱ¹³		
Hydromorphone, U	See Note ⁱ¹⁴		
Lorazepam, U	See Note ⁱ¹⁵		
MDA, U	See Note ⁱ¹⁶		
MDEA, U	See Note ⁱ¹⁷		
MDMA, U	See Note ⁱ¹⁸		
Meperidine metabolite, U	See Note ⁱ¹⁹		
Methamphetamine, U	See Note ⁱ²⁰		
Methylphenidate, U	See Note ⁱ²¹		
Midazolam, U	See Note ⁱ²²		
Morphine, U	See Note ⁱ²³		
Naloxone, U	See Note ⁱ²⁴		
Norbuprenorphine, U	See Note ⁱ²⁵		
Nordiazepam, U	See Note ⁱ²⁶		
Norfentanyl, U	See Note ⁱ²⁷		
Norhydrocodone, U	See Note ⁱ²⁸		
Noroxycodone, U	See Note ⁱ²⁹		
Noroxymorphone, U	See Note ⁱ³⁰		
Oxazepam, U	See Note ⁱ³¹		
Oxycodone, U	See Note ⁱ³²		
Oxymorphone, U	See Note ⁱ³³		
Phentermine, U	See Note ⁱ³⁴		
Pregabalin, U	See Note ⁱ³⁵		
Tapentadol, U	See Note ⁱ³⁶		
Tapentadol-o-Sulf, U	See Note ⁱ³⁷		
Temazepam, U	See Note ⁱ³⁸		

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272**Report Request ID:** 21654085**Printed:** 8/27/2026 08:27 MDT

Page 1 of 8

Tgt drug prof, MassSpec/EMIT, UR, |Received: 8/18/2026 15:43 MDT Report/Verified: 8/18/2026 16:19 MDT

Procedure	Result	Units	Reference Interval
Zolpidem, U	See Note ⁱ³⁹		
Zolpidem Metabolite, U	See Note ⁱ⁴⁰		
Targeted Drug Profile Comment	See Note ⁱ⁴¹		
EER Targeted Drug Profile, U	See Note ^{f1}		
Barbiturates Screen, U	PresumptivePOS * ^{f2} ⁱ⁴²		
Cocaine Screen, U	PresumptivePOS * ^{f2} ⁱ⁴³		
Carisoprodol Screen, U	Negative ^{f3 i44}		
THC (Cannabinoids) Screen, U	Negative ^{f3 i45}		
Ethyl Glucuronide Screen, U	PresumptivePOS * ^{f2} ⁱ⁴⁶		
Methadone Metabolite Screen, U	Negative ^{f3 i47}		
Phencyclidine Screen, U	Negative ^{f3 i48}		
Tramadol Screen, U	Negative ^{f3 i49}		

Result Footnote

f1: EER Targeted Drug Profile, U
Authorized individuals can access the ARUP Enhanced Report with an ARUP Connect account using the following link.

Your local lab can assist you in obtaining the patient report if you don't have a Connect account.

f2: Barbiturates Screen, U, Cocaine Screen, U, Ethyl Glucuronide Screen, U

Presumptive positive by immunoassay. Testing by mass spectrometry is available on request.

f3: Carisoprodol Screen, U, Methadone Metabolite Screen, U, Phencyclidine Screen, U, THC (Cannabinoids) Screen, U, Tramadol Screen, U

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

Test Information

i1: 6-acetylmorphine, U
INTERPRETIVE INFORMATION: 6-acetylmorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i2: 7-Aminoclonazepam, U
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i3: Alpha-OH-Alprazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Alprazolam, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272

Report Request ID: 21654085

Printed: 8/27/2026 08:27 MDT

Page 2 of 8

Test Information

- i3: Alpha-OH-Alprazolam, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i4: Alpha-OH-Midazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i5: Alprazolam, U
INTERPRETIVE INFORMATION: Alprazolam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry
- i6: Amphetamine, U
INTERPRETIVE INFORMATION: Amphetamine, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i7: Buprenorphine, U
INTERPRETIVE INFORMATION: Buprenorphine, U

Positive Cutoff: 5 ng/mL
Methodology: Mass Spectrometry
- i8: Clonazepam, U
INTERPRETIVE INFORMATION: Clonazepam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i9: Codeine, U
INTERPRETIVE INFORMATION: Codeine, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry
- i10: Diazepam, U
INTERPRETIVE INFORMATION: Diazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i11: Fentanyl, U
INTERPRETIVE INFORMATION: Fentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry
- i12: Gabapentin, U
INTERPRETIVE INFORMATION: Gabapentin, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272**Report Request ID:** 21654085**Printed:** 8/27/2026 08:27 MDT

Page 3 of 8

Test Information

i12: Gabapentin, U
Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

i13: Hydrocodone, U
INTERPRETIVE INFORMATION:Hydrocodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i14: Hydromorphone, U
INTERPRETIVE INFORMATION:Hydromorphone, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i15: Lorazepam, U
INTERPRETIVE INFORMATION:Lorazepam, U

Positive Cutoff: 60 ng/mL
Methodology: Mass Spectrometry

i16: MDA, U
INTERPRETIVE INFORMATION:MDA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i17: MDEA, U
INTERPRETIVE INFORMATION:MDEA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i18: MDMA, U
INTERPRETIVE INFORMATION:MDMA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i19: Meperidine metabolite, U
INTERPRETIVE INFORMATION:Meperidine metabolite, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i20: Methamphetamine, U
INTERPRETIVE INFORMATION:Methamphetamine, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i21: Methylphenidate, U
INTERPRETIVE INFORMATION:Methylphenidate, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272

Report Request ID: 21654085

Printed: 8/27/2026 08:27 MDT

Page 4 of 8

Test Information

i21: Methylphenidate, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i22: Midazolam, U
INTERPRETIVE INFORMATION:Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i23: Morphine, U
INTERPRETIVE INFORMATION:Morphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i24: Naloxone, U
INTERPRETIVE INFORMATION:Naloxone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i25: Norbuprenorphine, U
INTERPRETIVE INFORMATION:Norbuprenorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i26: Nordiazepam, U
INTERPRETIVE INFORMATION:Nordiazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i27: Norfentanyl, U
INTERPRETIVE INFORMATION:Norfentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry

i28: Norhydrocodone, U
INTERPRETIVE INFORMATION:Norhydrocodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i29: Noroxycodone, U
INTERPRETIVE INFORMATION:Noroxycodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i30: Noroxymorphone, U
INTERPRETIVE INFORMATION:Noroxymorphone, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272

Report Request ID: 21654085

Printed: 8/27/2026 08:27 MDT

Page 5 of 8

Test Information

i30: Noroxymorphone, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i31: Oxazepam, U
INTERPRETIVE INFORMATION: Oxazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i32: Oxycodone, U
INTERPRETIVE INFORMATION: Oxycodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i33: Oxymorphone, U
INTERPRETIVE INFORMATION: Oxymorphone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i34: Phentermine, U
INTERPRETIVE INFORMATION: Phentermine, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i35: Pregabalin, U
INTERPRETIVE INFORMATION: Pregabalin, U

Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

i36: Tapentadol, U
INTERPRETIVE INFORMATION: Tapentadol, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i37: Tapentadol-o-Sulf, U
INTERPRETIVE INFORMATION: Tapentadol-o-Sulf, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i38: Temazepam, U
INTERPRETIVE INFORMATION: Temazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i39: Zolpidem, U
INTERPRETIVE INFORMATION: Zolpidem, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272

Report Request ID: 21654085

Printed: 8/27/2026 08:27 MDT

Page 6 of 8

Test Information

i39: Zolpidem, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
i40: Zolpidem Metabolite, U
INTERPRETIVE INFORMATION: Zolpidem Metabolite, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry
i41: Targeted Drug Profile Comment
Flagging indicates a positive result; not that the result is abnormal.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i42: Barbiturates Screen, U
INTERPRETIVE INFORMATION: Barbiturates Screen, U

Positive Cutoff: 200 ng/mL
Methodology: Immunoassay
i43: Cocaine Screen, U
INTERPRETIVE INFORMATION: Cocaine Screen, U

Positive Cutoff: 150 ng/mL
Methodology: Immunoassay
i44: Carisoprodol Screen, U
INTERPRETIVE INFORMATION: Carisoprodol Screen, U

Positive Cutoff: 100 ng/mL

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272

Report Request ID: 21654085

Printed: 8/27/2026 08:27 MDT

Page 7 of 8

Test Information

i44: Carisoprodol Screen, U

Methodology: Immunoassay

The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

i45: THC (Cannabinoids) Screen, U

INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U

Positive Cutoff: 50 ng/mL

Methodology: Immunoassay

i46: Ethyl Glucuronide Screen, U

INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U

Positive Cutoff: 500 ng/mL

Methodology: Immunoassay

i47: Methadone Metabolite Screen, U

INTERPRETIVE INFORMATION: Methadone Metabolite Screen, U

Positive Cutoff: 100 ng/mL

Methodology: Immunoassay

i48: Phencyclidine Screen, U

INTERPRETIVE INFORMATION: Phencyclidine Screen, U

Positive Cutoff: 25 ng/mL

Methodology: Immunoassay

i49: Tramadol Screen, U

INTERPRETIVE INFORMATION: Tramadol Screen, U

Positive Cutoff: 100 ng/mL

Methodology: Immunoassay

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900272**Report Request ID:** 21654085**Printed:** 8/27/2026 08:27 MDT

Page 8 of 8